Press release
Invitation to Nanoform's Q4 and FY 2023 Report Presentation
The company will hold an online presentation and conference call the same day at
The presentation will be broadcast live as a webcast available at:
https://ir.financialhearings.com/nanoform-q4-report-2023
Teleconference dial-in numbers:
Dial-in number to the teleconference will be received by registering via the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. Questions can be presented by this dial-in function.
https://conference.financialhearings.com/teleconference/?id=50046525
For further information, please contact:
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/invitation-to-nanoform-s-q4-and-fy-2023-report-presentation,c3930220
https://mb.cision.com/Main/18905/3930220/2610242.pdf
(c) 2024 Cision. All rights reserved., source